Analyst Ami Fadia of Needham maintained a Buy rating on Neurocrine, boosting the price target to $184.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ami Fadia has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong financial performance and growth potential. The company’s third-quarter earnings per share significantly surpassed market expectations, driven by robust sales of their products, particularly Crenessity and Ingrezza. This impressive performance underscores the company’s effective management and strategic initiatives.
Ami Fadia also notes the management’s proactive approach in expanding their sales force to sustain Ingrezza’s growth and enhance Crenessity’s market reach. Additionally, Neurocrine’s promising pipeline and upcoming catalysts, such as the advancement of valbenazine and NBI-‘770 in clinical trials, further strengthen the company’s outlook. These elements collectively contribute to the positive assessment of Neurocrine’s stock potential, justifying the Buy rating.